Bosmolisib Drug Asset Due Diligence Report 2026

This Bosmolisib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Bosmolisib can convert its Small molecule drug profile and PI3Kγ x PI3Kδ biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Bosmolisib (query alias: Bosmolisib)
Modality / target	Small molecule drug; PI3Kγ x PI3Kδ; PI3Kγ inhibitors, PI3Kδ inhibitors
Highest global status	Phase 2
Originator	Boryung Corp.
Active developers	Boryung Corp.

The MCP disease footprint includes Peripheral T-Cell Lymphoma, Immunoblastic Lymphadenopathy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07180771	Phase 2	Not yet recruiting	44	Primary endpoint not disclosed in English source
NCT05460364	Phase 1	Completed	36	Primary endpoint not disclosed in English source
NCT04018248	Phase 1	Completed	26	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

1701 A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Phase 1; n=26; evaluation: Positive. Reported fields: CBR = 47.4 % (95%CI, 24.5 - 71.1)

A phase 1a/b study of BR101801, a PI3Kγδ and DNA PK triple inhibitor, in adult patients with advanced hematologic malignancies.

Phase 1; n=12; evaluation: Positive. Reported fields: RP2D = 200 mg

A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies

Phase 1; n=11; evaluation: Positive. Reported fields: AE(grade 3) = 2 pts (skin reaction), 3 (hepa ~ ~ xicites)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Bosmolisib addresses Peripheral T-Cell Lymphoma, Immunoblastic Lymphadenopathy. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 17 matched transaction record(s) under the scope “target-level comparable: PI3Kγ x PI3Kδ.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PI3Kγ x PI3Kδ records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2023-07-24	The Infinity-MEI merger saga finally ends in shareholders sinking the deal	Not disclosed	Financial terms not disclosed
2023-04-13	MCC will assess eganelisib from Infinity in two combination trials, namely MARIO-275 for urothelial cancer and MARIO-3 for TNBC and RCC.	Phase 2	Financial terms not disclosed
2023-04-06	Adlai Nortye entered into an option agreement with Nippon Kayaku to further advance the commercialization of AN2025 in Japan.	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination therapy for treating abnormal cell growth”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma”. The milestone feed surfaced a patent-application signal described as “Combination of RAD51 inhibitor and anti-cancer therapeutic agent”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO